-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CfuLz9QJIXCEk6KnMqWM1af4mUA9wJIWW/89XDK0NeI27r/VkVT+uFyYj9212pbq 6NEugXYNSOrUgMWq6xBPkg== 0001230295-07-000137.txt : 20070220 0001230295-07-000137.hdr.sgml : 20070219 20070220171334 ACCESSION NUMBER: 0001230295-07-000137 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20070215 FILED AS OF DATE: 20070220 DATE AS OF CHANGE: 20070220 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SAVIENT PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000722104 STANDARD INDUSTRIAL CLASSIFICATION: MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833] IRS NUMBER: 133033811 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 BUSINESS PHONE: 7324189300 MAIL ADDRESS: STREET 1: ONE TOWER CENTER CITY: EAST BRUNSWICK STATE: NJ ZIP: 08816 FORMER COMPANY: FORMER CONFORMED NAME: BIO TECHNOLOGY GENERAL CORP DATE OF NAME CHANGE: 19920703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: YACHMETZ PHILIP K CENTRAL INDEX KEY: 0001250318 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-15313 FILM NUMBER: 07636343 MAIL ADDRESS: STREET 1: 501 LAFAYETTE AVE CITY: WYCKOFF STATE: NJ ZIP: 07481 4 1 yac159.xml X0202 4 2007-02-15 0 0000722104 SAVIENT PHARMACEUTICALS INC SVNT 0001250318 YACHMETZ PHILIP K C/O SAVIENT PHARMACEUTICALS, INC. ONE TOWER CENTER BLVD., 14TH FLOOR EAST BRUNSWICK NJ 08816 0 1 0 0 EVP, Chief Business Officer Common Stock, $.01 par value per share 2007-02-15 4 S 0 3051 14.4364 D 109007.0000 D Common Stock, $.01 par value per share 2007-02-15 4 A 0 20790 A 129797.0000 D Option to Purchase Common Stock, $.01 par value 14.4300 2007-02-15 4 A 0 36383 0 A 2008-02-15 2017-02-15 Common Stock, $.01 par value per share 36383.0000 36383.0000 D These shares were sold automatically pursuant to a binding contract under Rule 10b5-1 of the Securities Exchange Act of 1934, to cover tax withholding obligations in connection with the vesting of restricted stock granted on February 15, 2006. Represents the average sale price. The highest price at which shares were sold was $14.4500 and the lowest price at which shares were sold was $14.4200. The right to receive these shares is pursuant to a restricted stock grant and such shares issue and vest as to 33.3% on each of 2/15/08, 2/15/09 and 2/15/10, provided the grantee remains employed by the Company on these dates. These options will become exercisable as to 25% on each of 2/15/08, 2/15/09, 2/15/10 and 2/15/11, provided the optionee remains employed by the Company on these dates. By: /s/ Michelle Zelinski as Attorney-In-Fact for 2007-02-20 -----END PRIVACY-ENHANCED MESSAGE-----